Author

Y. Okuno

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 2 Microbiology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:host-pathogen & immune response· 2 Assay:protein structure· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

G.-J. Bekker· 2 shared H. Kimura· 2 shared M. Araki· 2 shared M. Yaguchi· 2 shared N. Kamiya· 2 shared S. Matsumoto· 2 shared T. Inagaki· 2 shared T. Murata· 2 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

G.-J. Bekker

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Molecular dynamics unveils multiple-site binding of inhibitors with reduced activity on the surface of dihydrofolate reductase

M. Araki, T. Ekimoto, K. Takemura, S. Matsumoto, Y. Tamura, H. Kokubo, G.-J. Bekker, T. Yamane, Y. Isaka, Y. Sagae, N. Kamiya, M. Ikeguchi, Y. Okuno

This study uses molecular dynamics to analyze inhibitor binding to DHFR, showing that reduced activity correlates with multiple-bound states on the protein surface.

bioRxiv · Mar 27, 2024Biophysics

Inhibition of the BMP pathway suppresses tumor growth via downregulation of EGFR in MEK/ERK-dependent colorectal cancer

S. Shimizu, J. Kondo, K. Onuma, K. Ota, M. Kamada, Y. Harada, Y. Tanaka, M. Adachi Nakazawa, Y. Tamada, Y. Okuno, K. Kawada, K. Obama, R. J. Coffey, Y. Fujiwara, M. Inoue

This study shows that inhibiting the BMP pathway suppresses colorectal cancer growth by reducing EGFR, and combining BMP and MEK inhibition enhances therapeutic effects in patient-derived organoids.

bioRxiv · Nov 1, 2022 · PreprintCancer Biology

Epstein-Barr virus tegument protein BGLF2 in exosomes released from virus-producer cells assists de novo infection

Y. Sato, M. Yaguchi, Y. Okuno, H. Ishimaru, S. Ozaki, T. Suzuki, T. Inagaki, M. Umeda, T. Watanabe, M. Fujimuro, T. Murata, H. Kimura

This study identifies BGLF2, an EBV tegument protein, as being encapsulated in exosomes that enhance viral infection by boosting gene expression and suppressing innate immunity.

bioRxiv · Jun 22, 2020 · PreprintMicrobiology

Exploring ligand binding pathways on proteins using hypersound-accelerated molecular dynamics

M. Araki, S. Matsumoto, G.-J. Bekker, Y. Isaka, Y. Sagae, N. Kamiya, Y. Okuno

This study accelerates molecular dynamics simulations using ultrasound to study ligand binding pathways on proteins, revealing previously undetectable kinetic features and binding pathways.

bioRxiv · Apr 6, 2020Biophysics

Direct evidence of abortive lytic infection-mediated establishment of Epstein-Barr virus latency during B-cell infection

T. Inagaki, Y. Sato, J. Ito, M. Takaki, Y. Okuno, M. Yaguchi, H. M. A. A. Masud, T. Watanabe, K. Sato, S. Iwami, T. Murata, H. Kimura

The paper tracks EBV infection in B-cells using fate mapping and RNA-seq, showing abortive lytic infection precedes latency.

bioRxiv · Mar 23, 2020Microbiology